Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results And Recent Portfolio Execution menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Kiniksa Pharmaceuticals, Ltd : Kiniksa Pharmaceuticals Provides Corporate Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
– ARCALYST® 2023 net product revenue grew ~90% year-over-year to $233.1 million – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart Phase 2.